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Why was the cohort set up?
EXCEED aims to develop understanding of the genetic, en-
vironmental and lifestyle-related causes of health and dis-
ease. Cohorts like EXCEED, with broad consent to study
multiple phenotypes related to onset and progression of
disease and drug response, have a role to play in medicines
development, by providing genetic evidence that can iden-
tify, support or refute putative drug efficacy or identify
possible adverse effects.1 Furthermore, such cohorts are
well suited to the study of multimorbidity.
Multimorbidity describes the presence of multiple dis-
eases or conditions in one patient, though definitions in the
literature vary widely.2–4 It demands a holistic approach to
optimize care and avoid iatrogenic complications, such as
drug interactions. In the context of increasing specialisation
of many health care systems and high health care use among
people with multimorbidity, providing such care poses a
complex challenge.5–7 In high-income countries, multimor-
bidity is particularly common among more deprived socio-
economic groups and may even be considered as the norm
amongst older people,8,9 and an ageing global population
and a growing burden of non-communicable diseases in
low- and middle-income countries compound its global im-
portance.10 An expert working group convened by the UK
Academy of Medical Sciences recently highlighted the lack
of available evidence relating to the burden, determinants,
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prevention and treatment of multimorbidity, and recom-
mended the prioritisation of research on multimorbidity
spanning the translational pathway from understanding of
its biological mechanisms to health services research.11
Studies designed to investigate multimorbidity, rather
than considering individual conditions in relative isolation,
are therefore vital.6,7 Linkage to electronic health records
(EHR) has enabled information on a broad range of dis-
eases and risk factors to be studied in EXCEED and places
multimorbidity at the study’s heart. The EHR linkage also
facilitates longitudinal follow-up over an extended period,
enabling, for example, the investigation of lifestyle factors
and other exposures on healthy ageing and outcomes in
later life.
Combining wide-ranging data from EHR with genome-
wide genotyping is also central to EXCEED’s purpose. In
recent years, our understanding of which genes are associ-
ated with both rare and common diseases has advanced
rapidly as available sample sizes for genome-wide associa-
tion studies (GWAS) have grown rapidly.12 For example,
there are now 279 genetic variants associated with lung
function and chronic obstructive pulmonary disease
(COPD).13–25 However in many cases, our understanding
of the mechanisms through which these variants influence
disease risk—and which could therefore be therapeutic tar-
gets—is relatively limited. An efficient design to inform
this understanding is to stratify participants based on avail-
able study data on their health status (phenotype) or
genetic risk factors (genotype), to thus recall them for fur-
ther detailed investigations which would be impracticable
across a whole cohort. EXCEED was purposely designed
as a resource for recall-by-genotype sub-studies, and all
participants have consented to be recalled on this basis.
The study is led by the University of Leicester, in part-
nership with University Hospitals of Leicester NHS Trust
and in collaboration with Leicestershire Partnership NHS
Trust, local general practices and smoking cessation
services.
Who is in the cohort?
Recruitment to the cohort has taken place since 22
November 2013, primarily from the general population
through general practices in Leicester City, Leicestershire
and Rutland. In total, 10 156 participants have been
recruited to 4 December 2018. Of these, 445 were
recruited through smoking cessation services in Leicester
City, Leicestershire and Rutland, 44 through targeted re-
cruitment of those with a recorded diagnosis of COPD in
their electronic primary care record and 117 through addi-
tional community-based recruitment focused on Leicester’s
South Asian communities (see Figure 1). Although a
recruitment target of 10 000 has now been reached,
community-based recruitment particularly focusing on mi-
nority ethnic groups will continue subject to further
funding.
All tables in this paper present participants recruited via
primary care or smoking cessation, whose data were col-
lected and quality control undertaken at 4 December 2018
(9384 participants for questionnaire data, 8930 partici-
pants for primary care data). Quality control for the
remaining questionnaires and linkage to primary care data
are ongoing. Around 400 participants do not have ques-
tionnaire data but were recruited as consent and a saliva
sample were provided.
In the UK, over 98% of the population is registered with
a National Health Service (NHS) general practitioner.26 For
recruitment through primary care, all registered patients
aged between 40 and 69 years in participating general prac-
tices were eligible for recruitment. Exclusion criteria were
minimal: those receiving palliative care, those with learning
disabilities or dementia and those whose records indicated
they had declined consent for record sharing for research.
All eligible patients identified through primary care were
sent an initial letter with brief information about the study
and a reply slip to indicate their interest.
For participants recruited via smoking cessation serv-
ices, the lower age limit was reduced to 30 years because of
the higher risk of disease among smokers. Initial eligibility
screening and information provision were either under-
taken through electronic client records followed by a letter
to the client (as in primary care) or face-to-face by a smok-
ing cessation adviser during a routine appointment.
Additionally, patients with a recorded diagnosis of COPD
were invited from four local general practices with a higher
prevalence of COPD, to boost the numbers available for a
sub-study of respiratory disease. For this group, the lower
age limit was 30 years, and all other exclusion criteria were
identical to the main primary care recruitment.
All those who responded to indicate they were inter-
ested in taking part were sent full written information on
the study, in addition to a study consent form. Full infor-
mation regarding participant consent can be found
at [http://www.leicsrespiratorybru.nihr.ac.uk/our-research/
our-research-studies/exceed]. All participants consent to
follow-up of their electronic health care records for up to
25 years, to storage and analysis of their DNA sample and
to being contacted for further studies on the basis of their
genetic data (recall-by-genotype) or health status (recall-
by-phenotype). They may also consent or decline to be
contacted regarding genetic variants which may, in the fu-
ture, be considered clinically relevant.
Participants proceeded via one of two routes depending
on their location and personal preference: a face-to-face
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appointment with a research professional, or by post. The
flow of participants through the main primary care recruit-
ment route is illustrated in Figure 2. Approximately 8% of
those who received an initial invitation via primary care
completed recruitment. Table 1 gives an overview of the
demographic characteristics of the primary care population
sampled, compared with the characteristics of those
recruited to the study via primary care. Participants in the
Figure 1. Recruitment methods and numbers.
Figure 2. Recruitment via primary care.
Table 1. Demographic characteristics of the primary care population sampled for the study and those who participated (via the
primary care recruitment route only)
Primary care populationa Recruited Difference in proportions
(95% confidence interval)
Age (years) n (N ¼ 117 965) % n (N ¼ 8979) %
(<45) 21 057 17.9 661 7.4 10.5 (9.9 to 11.1)
(45–54) 44 559 37.8 2264 25.2 12.6 (11.6 to 13.5)
(55–64) 36 133 30.6 3365 37.5 6.9 (5.8 to 7.9)
( 65) 16 216 13.7 2689 29.9 16.2 (15.2 to 17.2)
Sex n (N ¼ 117 965) % n (N ¼ 8979) %
Male 59 003 50.0 3993 44.5 5.5 (4.5 to 6.6)
Female 58 962 50.0 4986 55.5 5.5 (4.5 to 6.6)
Ethnicity n (N ¼ 81 947) % n (N ¼ 8937) %
White 59 576 72.7 8284 92.7 20.0 (19.4 to 20.6)
Asian/Asian British 17 670 21.6 427 4.8 16.8 (16.3 to 17.3)
Black/African/Caribbean/Black British 2763 3.4 12 0.1 3.3 (3.1 to 3.4)
Mixed 686 0.8 93 1.0 0.2 (0.02 to 0.4)
Chinese 301 0.4 56 0.6 0.2 (0.08 to 0.4)
Other 951 1.2 65 0.7 0.5 (0.2 to 0.6)
aPrimary care population is all patients within the eligible age range in the practices sampled, and includes those who were excluded at the next step (codes for
palliative care, dementia, learning disability, or lack of consent to share data for research).
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study were older and more likely to be female than the
primary care population from which they were drawn.
This reflects well-known patterns of participation in
similar cohorts.27,28 The local primary care population
includes a large proportion of minority ethnic groups,
especially Asian and Asian British. These groups are
under-represented among study participants, although the
proportion of study participants of Asian and Asian British
ethnicity (5%) is higher than many UK cohorts, including
UK Biobank.28 This reflects experience of similar recruit-
ment methods in other studies.29 Explanations for the
under-representation of minority ethnic groups in medical
research more generally include language barriers, inequi-
table access to health care services, cultural sensitivities
and a lack of awareness of medical research and its pur-
pose.30,31 Community-based recruitment has been intro-
duced to EXCEED to improve representation of these
groups.
How often have they been followed up?
Participants have consented to follow-up through linkage
to EHR for up to 25 years. Linkage to electronic primary
care records (i.e. records from the participant’s general
practice) is undertaken upon completion of recruitment at
each practice and has been completed for 8930 partici-
pants to 4 December 2018.
As participants are prospectively followed up, we ex-
pect losses due to deaths (to date less than 1% of partici-
pants), withdrawals (to date less than 0.1% of
participants), relatively few losses due to house moves
within the UK or changing general practitioner (as NHS
patients retain the same NHS number and their electronic
records move with them) and some losses due to emigra-
tion. Analyses of historical health care records to track dis-
ease development and progression may be subject to
selection bias, in particular survivor bias.
What has been measured?
There are several phases of data collection, summarised in
Table 2. Linked primary care data provide historical co-
hort data. Since the mid-1990s, prospectively recorded
consultations enable the retrieval of information not only
on symptoms for which participants have visited their gen-
eral practitioner and diagnoses which have been made, but
also on examination findings (including blood pressure
readings and spirometry results, for example), laboratory
test results, drug prescriptions and secondary care referrals.
Major diagnoses documented on paper records before the
mid-1990s were retrospectively coded at the time of com-
puterization and so can also be retrieved.
Baseline data collection for all participants included a
self-completion questionnaire which collected detailed
Table 2. Summary of data collected at each phase
Phase Measurements
Historical cohort data Historically coded primary care data, transferred from paper records at the time of practice computeriza-
tion, approximately mid-1990s, and since mid-1990s prospectively recorded consultations, with
coded:
• symptoms
• diagnoses
• measurements, such as blood pressure and spirometry
• laboratory test results
• drug prescriptions
• secondary care referrals
Baseline All participants:
• Questionnaire, including smoking and alcohol use
• DNA saliva sample
Postal participants only: self-measured height, weight, waist circumference.
Examination by research professional only: height, weight, waist circumference, hip
circumference and spirometry
Ongoing Planned updates to primary care record linkage (detailed above), with consent to follow-up for 25 years,
to track health longitudinally
Ongoing linkage to:
• admissions, accident and emergency attendances and outpatient appointments via hospital episode
statistics
• Pathology data (East Midlands Pathology Service)
• Myocardial Ischaemia National Audit (MINAP)
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information on current and past smoking habits, smoking
cessation attempts, e-cigarette and shisha usage, environ-
mental tobacco smoke (second-hand smoke) exposure and
alcohol use. For those recruited via a face-to-face appoint-
ment, this was undertaken during the appointment. Those
participating by post completed the questionnaire online
using their own computer, with a paper version available if
necessary. Height, weight and waist circumference were ei-
ther measured by a research professional or self-reported
by postal participants. Those recruited face-to-face also
had their hip circumference measured and, where feasible,
underwent spirometric measurement of lung function.
Finally, a saliva sample was collected from all partici-
pants either at their appointment or returned by post, for
extraction of DNA. The samples are stored at the NIHR
Biocentre (Milton Keynes, UK), providing industrial-scale
laboratory information management and automated ro-
botic systems which have been shown to facilitate efficient
error-free sample storage and extraction from freezers in
the UK Biobank study.32 To date, genome-wide genotype
data (using the Affymetrix UK Biobank Axiom Array) are
available for 5216 participants after quality control, en-
abling analysis of over 40 million variants after imputation
to the Haplotype Reference Consortium (HRC) panel.33
Planned updates to linked primary care records will en-
able longitudinal tracking of health. There is also ongoing
linkage to other sources of health data including: admis-
sions, accident and emergency attendances and outpatient
appointments via hospital episode statistics; pathology
data (East Midlands Pathology Service); and the
Myocardial Ischaemia National Audit (MINAP).
What has it found? Key findings and
publications
Table 3 shows that, in general, our cohort is slightly
healthier than average for common health risk factors and
behaviours. This is similar to findings by other cohort stud-
ies.28 For example, the total proportion of participants
who were overweight, obese or morbidly obese (64.2%)
was slightly lower than similar age groups in Health
Survey for England 2016, where it was above 70% for all
ages from 45 upwards.34
Similarly, the proportion of EXCEED participants who
currently smoke is 9.7%, considerably lower than the na-
tional average (15.8%) and comparable only to the oldest
age group (65 and over) in the national Annual Population
Survey, among whom smoking prevalence was 8.3%.
Smoking prevalence among all younger age groups nation-
ally is 15% or above. On the other hand, the proportion of
people who report never smoking is also lower than in na-
tional population surveys. This may be influenced by
question wording and interpretation: whereas the relevant
national survey asked if people had ever ‘regularly’
smoked, the EXCEED questionnaire included occasional
use in the definition of ever smokers.35 Table 4 presents
more detailed information on smoking habits among cur-
rent and ex-smokers. The vast majority of both current
and ex-smokers reported smoking cigarettes, but cigar/cig-
arillo and pipe smoking was less common amongst current
than ex-smokers. Alcohol intake for our cohort is compa-
rable to that of similar age groups in Health Survey for
England 2016.36
Only 25.2% of participants are in the two most de-
prived national quintiles and 29.3% are in the least de-
prived quintile. For Leicester City, 75.9% of the
population are in the two most deprived quintiles and only
1.4% are in the least deprived quintile.37 Though this
reflects the whole Leicester population, not just those aged
40–69 and registered with the GP practices that agreed to
take part in EXCEED, it indicates that the most deprived
communities are under-represented in the cohort.
The Quality and Outcomes Framework (QOF), intro-
duced in 2004, aims to improve the quality of care patients
Table 3. Prevalence of risk factors and health behaviours
n %
Deprivationa (n ¼ 9171)
1 (most deprived) 1204 13.1
2 1112 12.1
3 1659 18.1
4 2507 27.3
5 (least deprived) 2689 29.3
BMI (n ¼ 9285)
Underweight (<18.5) 98 1.1
Normal (18.5–24.9) 3221 34.7
Overweight (25–29.9) 3576 38.5
Obese (30–39.9) 2092 22.5
Morbidly obese (40) 298 3.2
Waist circumference (n ¼ 9103)
Low risk (males <94 cm, females <80 cm) 2954 32.5
Increased risk (males 94–102 cm; females 80–88 cm) 2442 26.8
High risk (males >102 cm; females >88 cm) 3707 40.7
Smoking statusb (n ¼ 9381)
Current smoker 912 9.7
Ex-smoker (regular or occasional) 3678 39.2
Never smoker 4791 51.1
Alcohol intake (units/week) (n ¼ 9335)
None 1792 19.2
Lower risk (<14 u) 4515 48.4
Increasing risk (females 14–35 u; males 14–50 u) 2374 25.4
Higher risk (females >35 u; males >50 u) 657 7.0
BMI, body mass index; u, units.
aIndex of multiple deprivation national quintiles by postcode.
bIncludes cigarettes, cigars, cigarillos, pipes or shisha.
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are given by rewarding practices for meeting specified
standards of care. Prevalence of 16 chronic conditions pri-
oritized for management in primary care by QOF is pre-
sented in Table 5. The figures presented are based on
presence of any qualifying diagnostic code [QOF business
rules v37, 2017/18] at any time in the patient’s record,
with no further exclusions or restrictions. For those condi-
tions where the national QOF prevalence is calculated in a
comparable way, prevalence in EXCEED is generally
slightly higher and in some cases markedly so. For exam-
ple, prevalence of hypertension in EXCEED was 28.2%
compared with 13.9% nationally. This is likely to be
largely due to our older population, since QOF covers all
ages.
The number of conditions per individual is summarized
in Table 6. We found that, overall, 27.2% of our partici-
pants had a recorded diagnostic code for more than one
QOF condition. This is in line with findings from a large
study of almost 100 000 individuals in the Clinical
Practice Research Database by Salisbury and colleagues,
who used a similar approach to define multimorbidity.5
They found that 16% of their population had a code for
more than one QOF condition, but this rose sharply with
age, reaching around 20% among 55- to 64-year-olds and
over 30% in 65- to 74-year-olds. Two further large UK-
based studies have used more comprehensive lists of con-
ditions to define multimorbidity, but limited their focus to
active morbidity only, and found prevalence of multimor-
bidity between 23.2% and 27.2% across all ages, rising
substantially with age to 50% or more among 65- to 74-
year-olds.8,38
We specifically examined primary care diagnoses of one
condition, COPD, for which we had independent
Table 4. Smoking history (self-reported by current or ex-
smokers)
Current smokers Ex-smokers
n % n %
Type of tobacco useda (n ¼ 905) (n ¼ 3675)
Cigarettesb 857 93.6 3603 97.8
Shisha 1 0.1 6 0.2
Cigars/cigarillos 46 5.0 252 6.8
Pipe 15 1.6 147 4.0
Other 13 1.4 2 0.1
Use of electronic cigarettes (n ¼ 909) (n ¼ 3675)
Ever 238 26.2 204 5.6
Never 671 73.8 3471 94.4
Smoking cessation aids
used (ever)c
(n ¼ 377) (n ¼ 3636)
NRT 117 31.0 464 12.6
Bupropion 5 1.3 40 1.1
Varenicline 54 14.3 231 6.3
Other 48 12.7 304 8.3
None 193 51.2 2655 72.2
Mean SD Mean SD
Pack-years of smokingd (n ¼ 520) (n ¼ 3167)
27.2 18.9 18.4 20.6
Cigarettes per day (n ¼ 562) (n ¼ 3197)
13.5 8.6 14.8 11.9
Age at smoking initiation
(years)
(n ¼ 776) (n ¼ 3645)
18.4 5.8 17.1 3.8
aPeople may use more than one type of tobacco, so percentages will not
add up to 100.
bFiltered, unfiltered and hand-rolled.
cOnly for quit attempts lasting at least 6 months. Denominator for percen-
tages is current smokers who have made a quit attempt lasting at least
6 months, or total number of ex-smokers. People may have used more than
one aid, so percentages will not add up to 100.
dOnly for cigarette smokers.
Table 5. Prevalence of chronic conditions
Condition na %
Atrial fibrillation 243 2.7
Asthma 1138 12.7
Cancer 619 6.9
Coronary heart disease 393 4.4
Chronic kidney disease (3a-5) 280 3.1
Chronic obstructive pulmonary disease 301 3.4
Depression 2023 22.7
Diabetes 826 9.2
Epilepsy 103 1.2
Heart failure 107 1.2
Hypertension 2516 28.2
Mental health (psychosis, schizophrenia and
bipolar affective disorder)
71 0.8
Osteoporosis 285 3.2
Peripheral arterial disease 51 0.6
Rheumatoid arthritis 122 1.4
Stroke 108 1.2
aNumber of participants with one occurrence at any time of a diagnostic
code listed in the Quality and Outcomes Framework for that condition; % is
out of all participants for whom primary care data were available (8930).
Table 6. Proportion of participants with multiple chronic
conditionsa
Number of chronic conditions n %b
1 2942 32.9
2 1531 17.1
3 610 6.8
4 218 2.4
5 70 0.8
6 or more 20 0.2
a16 chronic conditions prioritized for management in primary care by the
Quality and Outcomes Framework (see Table 5).
bOf participants with primary care data.
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diagnostic information from baseline spirometry.
Diagnosis of COPD defined by presence of a COPD code
in primary care data compared with COPD defined by
baseline spirometry results indicates that there is underdi-
agnosis of COPD in EXCEED participants: 84.8% of those
with GOLD stage 1–4 COPD and 71.9% of GOLD stage
2–4 were undiagnosed (Table 7). Existing estimates of the
proportion of COPD which is undiagnosed range from
around 60% to over 80%, depending on the setting and
population studied.39–43 Using comparable methodology
in a similar population to ours, Shahab and colleagues
found that 81.2% of those with spirometric COPD had no
respiratory diagnosis at all and over 95% had not been di-
agnosed with COPD.44 The slightly lower level of underdi-
agnosis in EXCEED (84.8% of those with spirometric
COPD had not received a COPD diagnosis) may be par-
tially attributable to recent improvements in case-finding,
and to our use of primary care records rather than self-
report to define diagnoses. Reasons posited for such exten-
sive underdiagnosis include a perception among clinicians
that COPD is solely a disease of elderly smokers, pessimis-
tic views of treatment, lack of availability or underuse of
spirometry,43,45 and the unreliability of self-reported
smoking status in clinical practice.44
To demonstrate the utility of EXCEED for enabling
cross-sectional or longitudinal studies of quantitative
traits, we examined some of the most common meas-
ures available in the primary care data and the numbers
of participants with one or more recordings of these
measures (Table 8). Table 9 shows the average values of
these measures.46 For example, 98.0% of participants
have two or more recordings of blood pressure and over
90% have four or more recordings. Mean systolic blood
pressure was 129.9 [standard deviation (sd) 13.9] and
mean diastolic blood pressure was 78.3 (sd 8.6)
(Table 9).
Table 7. Comparison of diagnosis of COPD as defined by COPD codes in primary care data and defined by baseline spirometrya
COPD defined by baseline spirometry using GOLD criteria
GOLD 1–4 GOLD 2-4
Yes No Yes No
n % n % n % n %
COPD code in primary care Yes 86 15.2 19 0.7 76 28.1 29 1.0
No 479 84.8 2643 99.3 194 71.9 2928 99.0
aFor participants with linked primary care data and baseline spirometry measures (n¼ 3227). All percentages are column percentages.
Table 8. Numbers of participants with multiple occurrences of a Read code for a quantitative measurement
1 record 2 records 3 records 4 records
n % n % n % n %
Blood pressure reading 8895 99.6 8748 98.0 8487 95.0 8093 90.6
Serum creatinine 8422 94.3 7492 83.9 6468 72.4 5599 62.7
Serum sodium 8417 94.3 7477 83.7 6447 72.2 5582 62.5
Serum potassium 8389 93.9 7435 83.3 6400 71.7 5546 62.1
Serum urea level 8415 94.2 7460 83.5 6414 71.8 5537 62.0
eGFRa 8227 92.1 7045 78.9 5883 65.9 4946 55.4
Serum triglyceride levels 8389 93.9 6950 77.8 5633 63.1 4669 52.3
Serum cholesterol level 8287 92.8 6852 76.7 5586 62.6 4680 52.4
Platelet count 8054 90.2 6918 77.5 5827 65.3 4873 54.6
Serum HDL cholesterol level 8340 93.4 6770 75.8 5411 60.6 4412 49.4
Serum LDL cholesterol level 8050 90.1 6415 71.8 5054 56.6 4091 45.8
Serum bilirubin level 7074 79.2 5889 65.9 4835 54.1 3989 44.7
Haemoglobin A1c level 6782 75.9 4800 53.8 3342 37.4 2383 26.7
Total white blood count 7991 89.5 6804 76.2 5674 63.5 4731 53.0
Eosinophil count 8030 89.9 6860 76.8 5728 64.1 4761 53.3
HDL and LDL, high- and low-density lipoprotein.
aGFR, glomerular filtration rate calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation.46
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Recall-by-phenotype study
Recalling by phenotype (see Figure 3) facilitates in-depth
study of disease mechanisms, with a reduced risk of bias as
with nested case-control studies.47 One such sub-study has
recalled EXCEED participants to take part in a study ex-
amining the microbiome in COPD cases and in smoking
and non-smoking controls.
Potential for recall-by-genotype studies
Future recall-by-genotype studies (Figure 3) are expected
to contribute to a deeper understanding of genetic variants
which may be potential therapeutic targets, by bringing
back participants for detailed assessments on the basis of
the known or suspected mechanism of the relevant gene.
Such recall-by-genotype sub-studies may investigate dis-
ease susceptibility, disease progression or drug response,
and though they could be interventional in design, most
will be observational studies.48 Observational studies of
this kind can provide evidence which is not susceptible to
reverse causation and to confounding by lifestyle factors,
given Mendelian randomization.49
Nested designs are also feasible, which do not rely on
recall of participants but which could be undertaken
quickly and inexpensively using stored biological samples
Table 9. Summary of values for selected measuresa
Term nb % Mean sd
Blood pressure reading (systolic, mmHg) 8895 99.6 129.9 14.0
Blood pressure reading (diastolic, mmHg) 8895 99.6 78.1 8.8
Serum creatinine level (umol/L) 8422 94.3 74.1 21.3
Serum sodium level (mmol/L) 8417 94.3 140.2 2.2
Serum potassium level (mmol/L) 8389 93.9 4.4 0.4
Serum urea level (mmol/L) 8415 94.2 5.7 1.6
eGFRc (mL/min/1.73 m2) 8227 92.1 82.4 10.5
Serum triglyceride levels (mmol/L) 8389 93.9 1.5 0.8
Serum cholesterol level (mmol/L) 8287 92.8 5.1 1.1
Platelet count observation (x 109/L) 8054 90.2 252.5 64.7
Serum HDL cholesterol level (mmol/L) 8340 93.4 1.6 0.5
Serum LDL cholesterol level (mmol/L) 8050 90.1 2.9 0.9
Serum bilirubin level (umol/L) 7074 79.2 10.5 6.8
Haemoglobin A1c level (%) 6782 75.9 5.7 0.8
nb % Median IQR
Total white blood count (x 109/L) 7991 89.5 6.2 5.2–7.4
Eosinophil count (x 109/L) 8030 89.9 0.16 0.10–0.24
aWhere participants have more than one recording of a measure, the most recent value for each participant was used.
bNumber of participants for whom values were available.
cGlomerular filtration rate calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation.46
Figure 3. Examples of potential recall-by-phenotype (top) and recall-by-genotype studies (bottom).
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and linked electronic data, and such sub-studies could se-
lect samples based on either phenotype or genotype. Small-
scale intervention-by-genotype studies could, for example,
evaluate response to a treatment with a known safety pro-
file in participants with a specific genetic variant.
What are the main strengths and
weaknesses?
Linkage to EHR is a key strength of EXCEED, enabling
the study of a wide range of risk factors and diseases, even
where data have not been specifically collected at baseline
or precede enrolment as a study participant. UK general
practice has had over 20 years of near-universal computer-
ized records.50 These records have been further enhanced
with the introduction of the QOF in 2004, which incentiv-
ized GPs to keep comprehensive records of several chronic
diseases.51 Some of these indicators incentivize the record-
ing of quantitative traits relevant to the chronic disease di-
agnosed, such as blood pressure, lung function, estimated
glomerular filtration rate, glycated haemoglobin (HbA1c)
and cholesterol measures. That these are expected to be
recorded approximately annually means that registered
patients often have many repeat measures within linked
EHRs, providing an excellent opportunity to study trends
in control of conditions such as hypertension or progres-
sion of diseases such as COPD. Previous studies have vali-
dated some of these primary care measures—for example,
routinely recorded spirometry has shown good validity
when compared with study specific measures.52 Other more
complex longitudinal outcomes—for example, related to
healthy ageing—can also be measured using EHRs.
The use of EHR can have limitations. Misclassification
and miscoding of diagnoses may occur, and it is particu-
larly likely that the true prevalence of many diseases will
be underestimated (the ‘clinical iceberg’), as demonstrated
by a comparison of COPD diagnoses in primary care data
in EXCEED with COPD from spirometry (Table 7).
However, the availability of repeat recordings and multiple
types of data (including examination findings, pathology
results and onwards referrals) over a long period of time
can be used to improve and validate the classification of di-
agnoses and other important exposures and outcomes.
Many disease definitions have been validated already—for
example, definitions of COPD and asthma in the GOLD-
CPRD database—and EXCEED will contribute further to
this important area of study.53–59 In addition to disease sta-
tus validation, combining records of drug prescriptions
and diagnostic and symptom codes can be used to define
complex phenotypes that it has not been possible to study
previously.
The cohort recruited adults aged between 30 and
69 years, mostly aged 40 or over, and therefore permits the
study of a wide range of questions pertaining to health and
disease in adulthood. The absence of younger participants
renders it less suitable to study the evolution of disease be-
fore age 40. This is mitigated by the availability of linked
health care data from EHR. These records include data
prospectively coded by primary care practitioners from the
mid-1990s onwards, and will therefore include extensive
data from early adulthood for those in middle age when
recruited. Earlier life events, for example in childhood and
adolescence, are likely to be captured only when they were
transferred from paper to electronic health care records in
the early 1990s, and will therefore include major events
such as childhood pneumonia but not more minor illnesses.
The very elderly are also currently absent from the cohort,
but data will become available through follow-up of those
recruited at the older end of the age spectrum. More gener-
ally, the cohort’s age, sex and ethnicity distribution will
influence generalizability of research findings to other pop-
ulation groups, and for some research questions, validation
in other cohorts may be required.
Minority ethnic groups, notably Leicester’s Asian and
Asian British population, are currently under-represented in
EXCEED. This reflects the recruitment methods used to date.
We have extended recruitment to increase minority ethnic
participant numbers and have adapted our recruitment meth-
ods to achieve this, for example by undertaking recruitment at
community events. Minority ethnic groups are also substan-
tially under-served in the availability of samples with genome-
wide genotype data worldwide. Although the situation has
improved in recent years for Asian populations, only 14% of
individuals included in genome-wide association studies
worldwide up to 2016 were from Asian backgrounds.60 This
situation is replicated in UK-based studies. In UK Biobank,
only 2% of participants are from Asian or Asian British ethnic
groups, despite this group representing around 7% of the UK
population. It is essential that representation of minority eth-
nic groups increases substantially in genomic studies if these
communities are to realise the benefits of genomically-in-
formed advances in precision medicine. EXCEED aims to
contribute towards this important goal.
The utility of combining EHR and genetic data for effi-
cient and flexible genetic studies has been highlighted
by the eMERGE network of biobanks and Geisinger
MyCode.61,62 The comprehensive nature and near-
universal coverage of NHS health records adds further
strength to this study design. In particular, the ability to
capture virtually all primary and secondary care contacts
over decades of the lifespan enables longitudinal studies
with a depth of data available in relatively few studies.
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Strengths of the study also include consent from all
participants to be contacted to participate in recall-
by-genotype studies, a type of consent which is not yet
widely sought in cohort studies. Recall-by-genotype studies
are expected to be highly valuable to identify and validate
drug targets and to inform targeting of therapeutics in a
precision medicine approach.48 Maintaining the engage-
ment of cohort participants is important for such studies.
Potential strategies include incentivizing and/or reducing
barriers to further participation, building a study ‘commu-
nity’ through study branding, newsletters and events, and
efforts to trace participants where contact details have
lapsed.63,64 In EXCEED, in addition to a study newsletter,
we are devising approaches with our patient and public in-
volvement (PPI) group, including planned focus groups on
dynamic consent approaches.65
Some studies incorporating genetic analyses (such as
Genomics England) actively seek clinically actionable var-
iants, whereas most cohort studies may not seek to identify
these but may discover them as incidental findings.
Anticipating this potential, at the time of consent we asked
whether participants would wish to be notified about clini-
cally actionable variants; 99.5% of participants stated that
they would wish to be informed in this situation. Clinically
actionable variants will be discussed with the regional clin-
ical genetics department of University Hospitals Leicester
NHS Trust and then reported back to participants on re-
quest for NHS validation. Understanding the reasons for
participants’ preferences, how these change over time and
how these can best be supported by future policies and pro-
cedures, will be of key importance for EXCEED and other
longitudinal cohort studies.
Can I get hold of the data? Where can I find
out more?
Participants have consented to their pseudonymized data
being made available to other approved researchers, and
we welcome requests for collaboration and data access.
Access to the resource requires completion of a proposal
form, including a lay summary of the proposed research.
Applications to access the resource will be assessed for
consistency with the data access policy and with the guid-
ance of the Scientific Committee, which has participant
representation. Access to the data will be subject to com-
pletion of an appropriate Data/Materials Transfer
Agreement and to necessary funding being in place.
Requests to collect new data or to use biological samples
may be subject to additional requirements. Interested
researchers are encouraged to contact the study manage-
ment team via exceed@le.ac.uk.
Profile in a nutshell
• EXCEED is a longitudinal population-based cohort
which facilitates investigation of genetic, environ-
mental and lifestyle-related determinants of a broad
range of diseases and of multiple morbidity, through
data collected at baseline and via electronic health
care record linkage.
• Recruitment has taken place in Leicester, Leicestershire
and Rutland since 2013 and is ongoing, with 10 156
participants aged 30-69 to date. The population of
Leicester is diverse and additional recruitment from
Black, Asian and minority ethnic (BAME) communities
is ongoing.
• Participants have consented to follow-up for up to
25 years through electronic health records (EHR).
• Data available include baseline demographics, an-
thropometry, spirometry, lifestyle factors (smoking
and alcohol use) and longitudinal health information
from primary care records, with additional linkage to
other EHR datasets planned. Patients have con-
sented to be contacted for recall-by-genotype and
recall-by-phenotype sub-studies, providing an impor-
tant resource for precision medicine research.
• We welcome requests for collaboration and data ac-
cess by contacting the study management team via
exceed@le.ac.uk.
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